This article is more than 5 years old. Information may no longer be current.
Ixekizumab Improved Disease Activity, Physical Function in Patients With Psoriatic Arthritis
Click Here to Manage Email Alerts
Use of ixekizumab for the treatment of psoriatic arthritis in biologic-naïve patients improved disease activity and physical function and inhibited progression of structural damage, according to results.
Researchers randomly assigned 417 patients (46% were men) with psoriatic arthritis who were naïve to biologic therapy to receive subcutaneous injections of placebo, adalimumab 40 mg once every 2 weeks, ixekizumab 80 mg once every 2 weeks or ixekizumab 80 mg once every 4 weeks.
Results showed ACR20 was achieved by significantly more patients treated with both ixekizumab doses vs. placebo. At 12 weeks and 24 weeks, researchers found significant improvements in disease activity and functional disability among the ixekizumab groups compared with placebo. The ixekizumab groups also had significantly less progression of structural damage at week 24 and greater clearance of plaque psoriasis, according to results.
Similar to ixekizumab, results showed patients who received adalimumab had significantly improved efficacy results vs. placebo. However, patients in the placebo group had less frequent treatment-emergent adverse events vs. patients in the ixekizumab groups and the adalimumab group, researchers noted. – by Casey Tingle
Disclosures: Mease reports grants, personal fees and non-financial support from Eli Lilly & Company, Merck, Novartis, AbbVie, Amgen, Bristol Myers Squibb, Celgene, Crescendo, Genentech, Janssen, Pfizer, UCB Pharma and Corrona. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts